- Natco Pharma share price hits 20 percent upper circuit at Rs 1,188.95 apiece, also its all-time high, in intraday on BSE, after the corporate initiated clinical test |phase III|clinical trial|clinical test"> phase III clinical trial to gauge the efficacy and safety of Molnupiravir capsules in mild COVID-19 patients.
Natco Pharma’s share price hits 20 percent upper circuit at Rs 1,188.95 apiece, also it’s an all-time high, in intraday on BSE, after the corporate initiated clinical test |phase III|clinical trial|clinical test”> phase III clinical trial to gauge the efficacy and safety of Molnupiravir capsules in mild COVID-19 patients in India. Natco’s clinical test has been planned in 32 hospitals across India. Natco Pharma’s stock price has surpassed its previous high of Rs 998 per share, touched within the previous session. Technically, the stock looks overbought and a correction looks likely, said an analyst. “Long-term investors should book some profits at current levels and appearance to shop for near 920- 940 levels for better returns within the future,” AR Ramachandran, Co-founder & Trainer, Tips2Trades, told Financial Express Online.
Pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication. Patients treated with Molnupiravir achieved response within 5 days of therapy indicating that the duration of treatment with Molnupiravir is brief, with the extra advantage of being an oral therapy. In traded volume terms, 3.27 lakh Natco Pharma shares have traded on BSE thus far in intraday, while a complete of 62.19 crore shares have exchanged hands on NSE.
After the Drug Controller General of India (DCGI) permitted Natco Pharma to commence manufacturing of the antifungal drug, namely, Amphotericin B, liposomal injection, which is crucial within the treatment of mucormycosis, often referred to as ‘Black Fungus,’ the stock hit 20 percent upper circuit. Further, the US Food and Drug Administration (US FDA) has given final clearance to the corporate for 2 new medicine applications, one among which is an anti-cancer drug. “We believe both these recent developments are long-term positive for the corporate, helping the stock to draw in investment,” Ashis Biswas at CapitalVia Global Research, told Financial Express Online.
On Monday, Natco Pharma announced that it’s received USFDA approval for Everolimus tablets in US markets. Natco’s partner BPI plans to launch 0.25 mg, 0.5 mg, and 0.75 mg strengths of the merchandise shortly. “The strengths of Everolimus are indicated within the Prophylaxis of organ rejection in kidney transplantation and liver transplantation,” the corporate said. In another release, Natco Pharma has received final approval from the US Food and Drug Administration (US FDA) for abbreviated new drug applications (ANDA) for Lenalidomide Capsules. the corporate alongside its marketing partner (Arrow International Limited) had settled litigation with Celgene. NATCO and Arrow shall launch the merchandise on agreed-upon launch dates within the future. within the afternoon deals, Natco Pharma pared a number of its gains to trade 9.37 percent higher at Rs 1,083.65 apiece.
(The stock recommendations during this story are by the respective research and brokerage. Financial Express Online doesn’t bear any responsibility for its investment advice. Please consult your investment adviser before investing.)